{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:01:45Z","timestamp":1791216105860,"version":"4.1.0"},"reference-count":38,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.3892\/mmr.2014.2792","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T09:44:04Z","timestamp":1414403044000},"page":"1469-1475","source":"Crossref","is-referenced-by-count":19,"title":["microRNA-99a inhibits cell proliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer"],"prefix":"10.3892","volume":"11","author":[{"given":"DEYAO","family":"WU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUNFENG","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUIXING","family":"PAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PING","family":"QU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JIAN","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,10,27]]},"reference":[{"key":"key20180108001700_b1-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"key20180108001700_b2-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2407-14-77","article-title":"Identification of oxidized protein hydrolase as a potential prodrug target in prostate cancer","volume":"14","author":"McGoldrick","year":"2014","journal-title":"BMC Cancer"},{"key":"key20180108001700_b3-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(08)60729-1","article-title":"Prostate cancer","volume":"371","author":"Damber","year":"2008","journal-title":"Lancet"},{"key":"key20180108001700_b4-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.amepre.2009.03.007","article-title":"Race\/ethnicity and the perception of the risk of developing prostate cancer","volume":"37","author":"Shavers","year":"2009","journal-title":"Am J Prev Med"},{"key":"key20180108001700_b5-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1158\/0008-5472.CAN-10-2587","article-title":"MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2","volume":"71","author":"Ma","year":"2011","journal-title":"Cancer Res"},{"key":"key20180108001700_b6-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","article-title":"Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?","volume":"9","author":"Filipowicz","year":"2008","journal-title":"Nat Rev Genet"},{"key":"key20180108001700_b7-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"key20180108001700_b8-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"key20180108001700_b9-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20180108001700_b10-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs - microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nature Rev Cancer"},{"key":"key20180108001700_b11-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"key20180108001700_b12-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrurol.2010.45","article-title":"Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors","volume":"7","author":"Schaefer","year":"2010","journal-title":"Nat Rev Urol"},{"key":"key20180108001700_b13-mmr-11-02-1469","first-page":"1183","article-title":"miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression","volume":"39","author":"Fendler","year":"2011","journal-title":"Int J Oncol"},{"key":"key20180108001700_b14-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urolonc.2008.10.021","article-title":"MicroRNAs and cancer: current state and future perspectives in urologic oncology","volume":"28","author":"Schaefer","year":"2010","journal-title":"Urol Oncol"},{"key":"key20180108001700_b15-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/00365599.2012.748821","article-title":"MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer","volume":"47","author":"Zhou","year":"2013","journal-title":"Scand J Urol"},{"key":"key20180108001700_b16-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.02.005","article-title":"MicroRNAs and cancer: short RNAs go a long way","volume":"136","author":"Ventura","year":"2009","journal-title":"Cell"},{"key":"key20180108001700_b17-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/1471-2407-12-546","article-title":"MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma","volume":"12","author":"Cui","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180108001700_b18-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/0008-5472.CAN-10-1031","article-title":"miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation","volume":"71","author":"Sun","year":"2011","journal-title":"Cancer Res"},{"key":"key20180108001700_b19-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"e20916","DOI":"10.1371\/journal.pone.0020916","article-title":"MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R","volume":"6","author":"Lerman","year":"2011","journal-title":"PloS One"},{"key":"key20180108001700_b20-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12032-012-0411-9","article-title":"MicroRNA-99a\/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma","volume":"30","author":"Sun","year":"2013","journal-title":"Med Oncol"},{"key":"key20180108001700_b21-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/gcc.20485","article-title":"Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution","volume":"46","author":"Nagayama","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180108001700_b22-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/bjc.2013.562","article-title":"MicroRNA-100\/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R\/mTOR signalling pathways","volume":"109","author":"Li","year":"2013","journal-title":"Br J Cancer"},{"key":"key20180108001700_b23-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"36677","DOI":"10.1074\/jbc.M111.270561","article-title":"MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma","volume":"286","author":"Li","year":"2011","journal-title":"J Biol Chem"},{"key":"key20180108001700_b24-mmr-11-02-1469","first-page":"1","article-title":"Structural and functional diversity in the FGF receptor multigene family","volume":"60","author":"Johnson","year":"1993","journal-title":"Adv Cancer Res"},{"key":"key20180108001700_b25-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/1097-0045(20010201)46:2<163::AID-PROS1020>3.0.CO;2-T","article-title":"Alternative splicing of fibroblast growth factor receptors in human prostate cancer","volume":"46","author":"Kwabi-Addo","year":"2001","journal-title":"Prostate"},{"key":"key20180108001700_b26-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1476-4598-12-83","article-title":"FGFR3 has tumor suppressor properties in cells with epithelial phenotype","volume":"12","author":"Lafitte","year":"2013","journal-title":"Mol Cancer"},{"key":"key20180108001700_b27-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1","article-title":"aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8","volume":"189","author":"Dorkin","year":"1999","journal-title":"J Pathol"},{"key":"key20180108001700_b28-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/1078-0432.CCR-10-2772","article-title":"FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation","volume":"17","author":"Azab","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180108001700_b29-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"BiochemJ"},{"key":"key20180108001700_b30-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.bbadis.2011.09.007","article-title":"Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-\u03baB","volume":"1812","author":"Ettelaie","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"key20180108001700_b31-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mc.20398","article-title":"FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappaB and activating protein-1","volume":"47","author":"Lungu","year":"2008","journal-title":"Mol Carcinog"},{"key":"key20180108001700_b32-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/onc.2010.566","article-title":"NF-\u03baB addiction and its role in cancer: \u2018one size does not fit all\u2019","volume":"30","author":"Chaturvedi","year":"2011","journal-title":"Oncogene"},{"key":"key20180108001700_b33-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-\u03baB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20180108001700_b34-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"key20180108001700_b35-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","article-title":"Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer","volume":"26","author":"Tomlinson","year":"2007","journal-title":"Oncogene"},{"key":"key20180108001700_b36-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/modpathol.2009.46","article-title":"FGFR3 mutations in prostate cancer: association with low-grade tumors","volume":"22","author":"Hern\u00e1ndez","year":"2009","journal-title":"Mod Pathol"},{"key":"key20180108001700_b37-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108001700_b38-mmr-11-02-1469","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.bjc.6602274","article-title":"Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer","volume":"92","author":"Gowardhan","year":"2005","journal-title":"Br J Cancer"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2014.2792\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T13:47:15Z","timestamp":1565963235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2014.2792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,27]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,10,27]]},"published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.3892\/mmr.2014.2792"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2014.2792","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,27]]}}}